Rezultati pretraživanja
  1. 🇨🇦 Devastating that Lorlatinib & Atezolizumab (For ALK+ and SCLC ) were not approved by HTA funding $$$$, despite strong evidence that shows OS. We Deserve to access to Life extending Meds.

    Prikaži ovu nit
  2. The safety profile of the combination was consistent with prior trials and the current label for dinutuximab

  3. 4. velj

    . of discusses the next steps with liquid biopsies in and its broader use in oncology

  4. 4. velj

    The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory , missing the primary endpoint of the phase II/III DISTINCT trial

  5. 4. velj

    Immune checkpoint inhibitors have yielded modest improvement in , but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches

  6. 2. velj

    Neural "Fingerprint" Enables Personalized SBRT Dose for Lung Cancer

  7. 2. velj

    FDA Approvals Boost Competition in Treatment Landscapes

  8. 1. velj

    NICE Recommends Against Frontline Osimertinib in EGFR-Mutant

  9. 1. velj

    "Ultrathin" Bronchoscopy Improves Care for Patients With Lung Nodules

  10. 1. velj

    FDA Grants Priority Review to Selpercatinib for RET Fusion+ and Thyroid Cancers

  11. Shockingly in Cancers Still Most Commonly Diagnosed in Emergency Admissions , this needs to Change via

  12. Early diagnosis is critical to improved and is key. Comprehensive low-dose CT screening programs would change this Cancer Stats

  13. 30. sij

    The FDA has scheduled an Oncology Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection

  14. 29. sij

    The 2020 VAPALS Summit kicks off in Atlanta on January 30 to bring together approximately 100 clinicians from 20 VA medical centers to discuss implementation strategies to reduce lung cancer mortality among Veterans with early detection annual low dose chest CT scans.

  15. 29. sij

    The Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+

  16. Meanwhile #433 die each day from Coronavirus terrifies us, but another virus has already killed 6,000 in US

  17. 29. sij

    We spoke with and of about remaining questions in immunotherapy and targeted therapy for advanced in this week's

  18. 29. sij

    The 2020 VAPALS Summit gives special thanks to Dr. Haval Balata who is traveling from Manchester, UK to deliver our Keynote Lecture. The program that he will discuss offers a model that appears feasible for .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.